Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression

Hypertension

Volumn 46, Issue 3, 2005, Pages 577-583

  Okumura, Midori ^a   Iwai, Masaru ^a   Ide, Ayumi ^a   Mogi, Masaki ^a   Ito, Masaharu ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Inflammation; Oxidative stress; Receptors, angiotensin; Remodeling

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYETHYLENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FEMORAL ARTERY; MALE; MOUSE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CONSTRICTION, PATHOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMORAL ARTERY; MALE; MICE; MICE, KNOCKOUT; OXIDATIVE STRESS; RECEPTOR, ANGIOTENSIN, TYPE 2; SEX CHARACTERISTICS; TETRAZOLES; VALINE; VASCULITIS; WOUNDS AND INJURIES;

EID: 25444533093     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000178564.14464.80     Document Type: Article

References (26)

1. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33: 613-621.
2. de Gasparo M, Catt KJ, Inagami T, Wright TW, Unger T. International Union of Pharmacology, XXIII: the angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
3. Shanmugam S, Corvol P, Gasc J-M. Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat. Hypertension. 1996;28:91-97.
4. 2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension. 1999;33:1414-1419.
5. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001;104:2716-2721.
6. 2 receptors in neointima formation. Circulation. 2002;106:847-853.
7. Koike G, Horiuchi M, Yamada T, Szpirer C, Jacob HJ, Dzau VJ. Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung. Biochem Biophys Res Commun. 1994;203:1842-1850.
8. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1996;93:10022-10227.
9. Liu H-W, Iwai M, Takeda-Matsubara Y, Wu L, Li J-M, Okumura M, Cui T-X, Horiuchi M. Effect of estrogen and AT, receptor blocker on neointima formation. Hypertension. 2002;40:451-457.
10. 1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension. 2005;45:1-7.
11. 2 receptor expression and signaling. Physiol Genomics. 2000;2:13-20.
12. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griendling KK. Upregulation of nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol. 2002;22:21-27.
13. 1 receptor blocker olmesartan. Hypertension. 2004;43:263-269.
14. Kolbeck RC, She ZW, Callahan LA, Nosek TM. Increased superoxide production during fatigue in the perfused rat diaphragm. Am J Respir Crit Care Med. 1997;156:140-145.
15. Zhang L, Fishman MC, Huang PL. Estrogen mediated the protective effects of pregnancy and chorionic gonadotropin in a mouse model of vascular injury. Arterioscler Thromb Vasc Biol. 1999;19:2059-2065.
16. Akishita M, Ouchi Y, Miyoshi H, Kozaki K, Inoue S, Ishikawa M, Eto M, Toba K, Orimo H. Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis. 1997;130:1-10.
17. Xing D, Miller A, Novak L, Rocha R, Chen Y-F, Oparil S. Estradiol and progesterone differentially modulate leukocyte infiltration after vascular injury. Circulation. 2004;109:234-241.
18. Bakir S, Mod T, Durand J, Chen Y-F, Thompson J-A, Oparil S. Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from the balloon-injured rat carotid artery model. Circulation. 2000;101: 2342-2344.
19. Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, Nahmias C, Ito M, Horiuchi M. Estrogen activates phosphatases and antagonizes growth-promoting effects of angiotensin II. Hypertension. 2002;39:41-45.
20. Wu L, Iwai M, Li Z, Shiuchi T, Min L, Cui T, Li J, Okumura M, Nahmias C, Horiuchi M. Regulation of inhibitory protein-κB by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol. 2004;18:666-678.
21. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
22. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-1052.
23. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075-1081.
24. Gragasin FS, Xu Y, Arenas IA, Kainth N, Davidge ST. Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23: 38-44.
25. Strehlow K, Rotter S, Wassmann S, Adam O, Grohe C, Laufs K, Bohm M, Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res. 2003;93:170-177.
26. 1 receptor antagonist. J Biol Chem. 2001;276: 39721-39726.